EGFR and head and neck cancer: Sapitinib, a 'quinazoline small' compound, showed the most exciting results, with EC50 concentrations in the nanomolar range in the four ‘responsive’ lines comparable to those observed in non‐small cell lung cancer (NSCLC) and head and neck cancer cell lines defined as being sensitive to EGFR 51.